Mesoderm posterior basic helix-loop-helix transcription factor 2 (MESP2)

Mesoderm posterior basic helix-loop-helix transcription factor 2 (MESP2) is a transcription factor belonging to the basic helix-loop-helix (bHLH) family that plays a pivotal role in embryonic somitogenesis, the process by which vertebral segments are formed[1][3][6][8]. MESP2 regulates the rostrocaudal patterning of somites, working primarily through interactions with the Notch signaling pathway[1][3][6][8]. It is highly expressed in the anterior presomitic mesoderm and is critical for the separation and formation of vertebral and rib structures; loss-of-function mutations lead to spondylocostal and spondylothoracic dysostosis syndromes, characterized by abnormal segmentation of the vertebrae and fusion of ribs[3][6][7]. Beyond skeletal development, MESP2 is also essential for specifying cardiac mesoderm and in certain contexts modulates cell cycle regulators, such as the SKP2/p27 axis, with emerging evidence of a tumor suppressor role in gastric cancer[5]. Its function is tightly regulated by temporal expression patterns and protein degradation mechanisms, making it a crucial developmental gatekeeper[1][3][5][6]. No drugs directly target MESP2, but its interaction profile and disease associations make it a focal point for developmental biology and new cancer research[1][5].

Other names

Class C basic helix-loop-helix protein 6bHLHc6SCDO2Mesoderm posterior protein 2Mesoderm posterior 2 homologBHLHC6

No direct, clinically validated mechanisms, but in research settings: Modulation of MESP2 expression can influence Notch pathway and cell cycle checkpoint genes (e.g., SKP2/p27 axis in cancer); Competitive binding to TCF4 suppresses Wnt/beta-catenin transcriptional activity.